The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life.

Trial Profile

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2013

At a glance

  • Drugs Galantamine (Primary) ; Nimodipine
  • Indications Alzheimer's disease; Vascular dementia
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 22 Jul 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 22 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Sep 2009 Actual patient number (22) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top